Gilead aims to expand CAR-T manufacturing capabilities post-Kite acquisition – BioPharma-Reporter.com
BioPharma-Reporter.com |
Gilead aims to expand CAR–T manufacturing capabilities post-Kite acquisition
BioPharma-Reporter.com Until the US Food and Drug Administration (FDA) approved the first gene modified cell therapy product in the form of Novartis' Kymriah (tisagenlecleucel), Gilead Science's agreement to buy Kite Pharma was the biggest CAR–T cell-related story of the … "Chemotherapy will become just a bad memory" Kite Pharma, Inc. (NASDAQ:KITE) Overbought but Is That a Sell Indicator? |
